We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+28.39%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.06B
AUM Growth
+$953M
Cap. Flow
+$556M
Cap. Flow %
10.99%
Top 10 Hldgs %
34.58%
Holding
150
New
52
Increased
21
Reduced
21
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$116M
2
ONCR
Oncorus, Inc.
ONCR
+$66M
3
TOI icon
The Oncology Institute
TOI
+$56.2M
4
CYTK icon
Cytokinetics
CYTK
+$45M
5
VTRS icon
Viatris
VTRS
+$40M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$196M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$142M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$96M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$74.4M
5
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
+$58.3M

Sector Composition

Rank Sector Weight
1 Healthcare 69.84%
2 Industrials 0.55%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PROF
76
Profound Medical
PROF
$263M
$14.3M 0.28%
695,000
– –
SRRK icon
77
Scholar Rock
SRRK
$5.92B
$14M 0.28%
+288,876
New +$10.5M
KNTE
78
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$13.7M 0.27%
+345,000
New +$13.8M
ELVN icon
79
Enliven Therapeutics
ELVN
$3.84B
$12.7M 0.25%
144,467
+15,054
+12% +$1.26M
DYN icon
80
Dyne Therapeutics
DYN
$4.28B
$12M 0.24%
570,000
+158,733
+39% +$3.14M
RNAM
81
DELISTED
Avidity Biosciences
RNAM
$11.6M 0.23%
453,973
-20,213
-4% -$589K
PMVP icon
82
PMV Pharmaceuticals
PMVP
$58.7M
$11.5M 0.23%
187,192
+137,192
+274% +$5.38M
COGT icon
83
Cogent Biosciences
COGT
$6.95B
$11.2M 0.22%
+1,000,000
New +$11M
TECX
84
Tectonic Therapeutic
TECX
$562M
$11.2M 0.22%
+66,667
New +$11.9M
EUCRU
85
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$10.7M 0.21%
+1,000,000
New +$10.2M
SRSAU
86
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$10.7M 0.21%
+1,000,000
New +$10.3M
MTACU
87
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$10.5M 0.21%
+1,000,000
New +$10.4M
CAPAU
88
DELISTED
HighCape Capital Acquisition Corp. Unit
CAPAU
$10.3M 0.2%
1,000,000
– –
SNRHU
89
DELISTED
Senior Connect Acquisition Corp. I Unit
SNRHU
$10.3M 0.2%
+1,000,000
New +$10.3M
TPTX
90
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$10.2M 0.2%
+83,846
New +$9.19M
STIM icon
91
Neuronetics
STIM
$130M
$10.2M 0.2%
919,000
-656,000
-42% -$4.93M
OM icon
92
Outset Medical
OM
$87.5M
$9.95M 0.2%
11,667
+3,334
+40% +$2.57M
BCAB icon
93
BioAtla
BCAB
$5.86M
$9.54M 0.19%
+5,608
New +$9.37M
DCTH icon
94
Delcath Systems
DCTH
$399M
$8.96M 0.18%
+500,000
New +$6.85M
TMPMU
95
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$7.7M 0.15%
+750,000
New +$7.59M
SIEN
96
DELISTED
Sientra, Inc.
SIEN
$7.46M 0.15%
191,812
-40,210
-17% -$1.8M
SILK
97
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.12M 0.14%
+113,000
New +$7.01M
TSHA icon
98
Taysha Gene Therapies
TSHA
$1.57B
$6.63M 0.13%
250,000
– –
CERE
99
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$6.38M 0.13%
+385,043
New +$5M
PANA.U
100
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$6.38M 0.13%
500,000
– –
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2020 Portfolio in Review

As of Q4 2020, Deerfield Management held 150 positions worth $5.06B, up 23% from $4.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management deployed $556M of net new capital in Q4 2020, opening 52 new positions and adding to 21 existing holdings. Its largest new stake was Biogen: 448,000 shares worth $110M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 62% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was DFP Healthcare Acquisitions Corp. Unit, an estimated $58.3M trimmed.

  • Deerfield Management's largest Q4 2020 buy was Biogen: 448,000 shares worth $110M.
  • Deerfield Management added most to Viatris in Q4 2020, an estimated $40M increase.
  • Deerfield Management's biggest Q4 2020 reduction was DFP Healthcare Acquisitions Corp. Unit, cutting an estimated $58.3M.
  • Deerfield Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $196M.
  • Deerfield Management's ten largest holdings make up 35% of its $5.06B portfolio in Q4 2020.
  • Deerfield Management opened 52 new positions and closed 24 in Q4 2020.
  • Deerfield Management's portfolio value rose 23% quarter-over-quarter to $5.06B.

Based on Deerfield Management's 13F filing for Q4 2020, filed 16 Feb 2021.